A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.

Anthony W. Tolcher, Patricia LoRusso, Afshin Dowlati et al.|Journal of Clinical Oncology|2021

Cited by 33